The PMC aims to accelerate the translation of potentially relevant diagnostic, prognostic and therapeutic findings into clinically actionable information by applying state-of-the-art technology in a clinical laboratory environment. Our partnerships and collaborations with industry, academia and healthcare organisations maximises the potential to capitalise on the value of integrated clinical and biomarker information to improve patient’s outcome.

The PMC extends along 563m², more than 300m² of which represent newly refurbished laboratory space. The PMC is a fully-integrated clinical biomarker laboratory, building up on the successful Molecular Pathology programme at QUB where 17 new high-quality clinical and scientific staff have been recruited, and over £2M investment in the latest technology in genomics, digital pathology and laboratory automation are in place. The PMC will operate within a structure of two core interconnected sections – Genomics and Tissue Hybridization & Digital Pathology, linked by a Bioinformatics team and supported by a dedicated management team. The PMC, working in partnership with the successful Northern Ireland Biobank (NIB), is integrated in an existing molecular programme honed by successful research grant funding investment of several million, infrastructure programmes and clinical trials.